指南与共识支持与姑息治疗乳腺癌

ASCO临床实践指南更新:癌症患者生育力保存

Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.
指南 / 共识 · J Clin Oncol · 2018-04-05

该指南基于2013年1月至2017年3月的系统文献回顾,由更新专家组评估61篇文献,未对2013年推荐做重大修改。推荐尽早与育龄患者或其父母讨论不育风险,提供生育力保存选项或转诊生殖专家,并记录讨论。精子、卵母细胞和胚胎冷冻为标准实践;GnRHa不推荐替代已证实方法,但在年轻乳腺癌患者中可考虑使用。

要点

  • 尽早与育龄癌症患者或患儿父母讨论不育风险及生育力保存选项。
  • 精子、卵母细胞和胚胎冷冻保存是标准实践,应广泛提供。
  • GnRHa不推荐替代已证实的生育力保存方法,年轻乳腺癌患者可考虑使用。

核心结论

  • 2013年ASCO生育力保存推荐未因2013年1月至2017年3月的新文献而发生重大改变。

研究设计与样本

  • 系统综述,检索PubMed和Cochrane Library从2013年1月至2017年3月发表的文献,更新专家组评估了61篇文献。

主要发现

  • 共识别并评估61篇文献,均未促使对2013年推荐做出重大修改。

关键数值与推荐

  • 精子、卵母细胞和胚胎冷冻保存被视为标准实践且广泛可用。
  • 有矛盾证据推荐GnRHa和其他卵巢抑制方法用于生育力保存。
  • 在已证实生育力保存方法不可行时,年轻乳腺癌患者可提供GnRHa以降低化疗诱导卵巢功能不全的可能性。
  • GnRHa不应替代已证实的生育力保存方法。
  • 卵巢组织冷冻保存领域进展迅速,未来可能成为标准治疗。

临床怎么用

  • 医护人员应尽早与育龄癌症患者或患儿父母/监护人启动不育可能性讨论。
  • 提供者应准备讨论生育力保存选项和/或转诊所有潜在患者至合适的生殖专家。
  • 应在治疗过程中尽早告知患者生育力潜在威胁,以保留最广泛的生育力保存选项。
  • 讨论应被记录。

局限性

  • 有矛盾证据推荐GnRHa和其他卵巢抑制方法用于生育力保存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To provide current recommendations about fertility preservation for adults and children with cancer. Methods A systematic review of the literature published from January 2013 to March 2017 was completed using PubMed and the Cochrane Library. An Update Panel reviewed the identified publications. Results There were 61 publications identified and reviewed. None of these publications prompted a significant change in the 2013 recommendations. Recommendations Health care providers should initiate the discussion on the possibility of infertility with patients with cancer treated during their reproductive years or with parents/guardians of children as early as possible. Providers should be prepared to discuss fertility preservation options and/or to refer all potential patients to appropriate reproductive specialists. Although patients may be focused initially on their cancer diagnosis, providers should advise patients regarding potential threats to fertility as early as possible in the treatment process so as to allow for the widest array of options for fertility preservation. The discussion should be documented. Sperm, oocyte, and embryo cryopreservation are considered standard practice and are widely available. There is conflicting evidence to recommend gonadotrophin-releasing hormone agonists (GnRHa) and other means of ovarian suppression for fertility preservation. The Panel recognizes that, when proven fertility preservation methods are not feasible, and in the setting of young women with breast cancer, GnRHa may be offered to patients in the hope of reducing the likelihood of chemotherapy-induced ovarian insufficiency. GnRHa should not be used in place of proven fertility preservation methods. The panel notes that the field of ovarian tissue cryopreservation is advancing quickly and may evolve to become standard therapy in the future. Additional information is available at www.asco.org/survivorship-guidelines .

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID: 29620997. doi:10.1200/JCO.2018.78.1914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。